Tobacco addiction and the dysregulation of brain stress systems

Neuroscience and Biobehavioral Reviews

Volumn 36, Issue 5, 2012, Pages 1418-1441

  Bruijnzeel, Adrie W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; Anxiety; CRF; Dependence; Depression; Hypocretin; Nicotine; Norepinephrine; NPY; Tobacco

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; [LEU31,PRO34]NEUROPEPTIDE Y; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ASTRESSIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CLONIDINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CRA 0450; DESIPRAMINE; IDAZOXAN; LOFEXIDINE; MECAMYLAMINE; METIROSINE; NEUROPEPTIDE Y; NEUROPEPTIDE Y [3-36]; NEUROPEPTIDE Y RECEPTOR AGONIST; NORADRENALIN; OREXIN; PEPTIDE YY; PLACEBO; PRAZOSIN; R 278995; REBOXETINE; RESERPINE; TETRABENAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; YOHIMBINE;

ANXIETY DISORDER; BRAIN; BRAIN STRESS SYSTEM; DEPRESSION; DRUG ABUSE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SMOKING; SMOKING CESSATION; STRESS; TOBACCO; TOBACCO DEPENDENCE;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MENTAL DISORDERS; NEUROPEPTIDE Y; NEUROPEPTIDES; NOREPINEPHRINE; PITUITARY-ADRENAL SYSTEM; TOBACCO USE DISORDER;

EID: 84859383568     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.02.015     Document Type: Review

References (386)

1. Acierno R.A., Kilpatrick D.G., Resnick H.S., Saunders B.E., Best C.L. Violent assault, posttraumatic stress disorder, and depression. Risk factors for cigarette use among adult women. Behav. Modif. 1996, 20:363-384.
2. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., Roberts G.W., Crow T.J., Tatemoto K., Polak J.M. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
3. Ague C. Nicotine and smoking: effects upon subjective changes in mood. Psychopharmacologia 1973, 30:323-328.
4. al'Absi M., Hatsukami D., Davis G.L. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology 2005, 181:107-117.
5. al'Absi M., Hatsukami D., Davis G.L., Wittmers L.E. Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend. 2004, 73:267-278.
6. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
7. Amstadter A.B., Nugent N.R., Koenen K.C., Ruggiero K.J., Acierno R., Galea S., Kilpatrick D.G., Gelernter J. Association between COMT, PTSD, and increased smoking following hurricane exposure in an epidemiologic sample. Psychiatry 2009, 72:360-369.
8. Anda R.F., Williamson D.F., Escobedo L.G., Mast E.E., Giovino G.A., Remington P.L. Depression and the dynamics of smoking. A national perspective. JAMA 1990, 264:1541-1545.
9. Andersson K., Siegel R., Fuxe K., Eneroth P. Intravenous injections of nicotine induce very rapid and discrete reductions of hypothalamic catecholamine levels associated with increases of ACTH, vasopressin and prolactin secretion. Acta Physiol. Scand. 1983, 118:35-40.
10. Andreoli V., Caillard V., Deo R.S., Rybakowski J.K., Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J. Clin. Psychopharmacol. 2002, 22:393-399.
11. Aricioglu F., Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann. N. Y. Acad. Sci. 2003, 1009:196-201.
12. ASPECT Consortium, 2005. Tobacco or Health in the European Union: Past, Present and Future.
13. Aston-Jones G. Brain structures and receptors involved in alertness. Sleep Med. 2005, 6(Suppl. 1):S3-S7.
14. Aston-Jones G., Cohen J.D. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu. Rev. Neurosci. 2005, 28:403-450.
15. Aston-Jones G., Harris G.C. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 2004, 47(Suppl. 1):167-179.
16. Badia-Elder N.E., Stewart R.B., Powrozek T.A., Roy K.F., Murphy J.M., Li T.K. Effect of neuropeptide Y (NPY) on oral ethanol intake in Wistar, alcohol-preferring (P), and -nonpreferring (NP) rats. Alcohol Clin. Exp. Res. 2001, 25:386-390.
17. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the anxiogenic response to ethanol withdrawal in the rat. Psychopharmacology 1991, 103:227-232.
18. Balfour D.J. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Nicotine Psychopharmacology, Series: Handbook of Experimental Pharmacology 2009, vol. 192:209-233.
19. Balfour D.J., Khullar A.K., Longden A. Effects of nicotine on plasma corticosterone and brain amines in stressed and unstressed rats. Pharmacol. Biochem. Behav. 1975, 3:179-184.
20. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology 1999, 146:290-296.
21. Barr A.M., Markou A., Phillips A.G. A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol. Sci. 2002, 23:475-482.
22. Barrantes G.E., Rogers A.T., Lindstrom J., Wonnacott S. Alpha-Bungarotoxin binding sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation with alpha 7 subunits and up-regulation by chronic nicotine treatment. Brain Res. 1995, 672:228-236.
23. Beckham J.C., Kirby A.C., Feldman M.E., Hertzberg M.A., Moore S.D., Crawford A.L., Davidson J.R., Fairbank J.A. Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict. Behav. 1997, 22:637-647.
24. Bell S.L., Taylor R.C., Singleton E.G., Henningfield J.E., Heishman S.J. Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving in drug abusers. Nicotine Tob. Res. 1999, 1:45-52.
25. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712.
26. Benowitz N.L. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N. Engl. J. Med. 1988, 319:1318-1330.
27. Berman R.M., Narasimhan M., Miller H.L., Anand A., Cappiello A., Oren D.A., Heninger G.R., Charney D.S. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker?. Arch. Gen. Psychiatry 1999, 56:395-403.
28. Bjornson W., Rand C., Connett J.E., Lindgren P., Nides M., Pope F., Buist A.S., Hoppe-Ryan C., O'Hara P. Gender differences in smoking cessation after 3 years in the lung health study. Am. J. Public Health 1995, 85:223-230.
29. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15:220-226.
30. Blomqvist A.G., Herzog H. Y-receptor subtypes - how many more?. Trends Neurosci. 1997, 20:294-298.
31. Boutrel B., Kenny P.J., Specio S.E., Martin-Fardon R., Markou A., Koob G.F., de L.L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19168-19173.
32. Breslau N., Kilbey M.M., Andreski P. DSM-III-R nicotine dependence in young adults: prevalence, correlates and associated psychiatric disorders. Addiction 1994, 89:743-754.
33. Breslau N., Klein D.F. Smoking and panic attacks: an epidemiologic investigation. Arch. Gen. Psychiatry 1999, 56:1141-1147.
34. Broberger C., Hokfelt T. Hypothalamic and vagal neuropeptide circuitries regulating food intake. Physiol. Behav. 2001, 74:669-682.
35. Brown Z.W., Amit Z., Rockman G.E. Intraventricular self-administration of acetaldehyde, but not ethanol, in naive laboratory rats. Psychopharmacology 1979, 64:271-276.
36. Bruijnzeel A.W. kappa-Opioid receptor signaling and brain reward function. Brain Res. Rev. 2009, 62:127-146.
37. Bruijnzeel A.W., Bishnoi M., van Tuijl I.A., Keijzers K.F., Yavarovich K.R., Pasek T.M., Ford J., Alexander J.C., Yamada H. Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology 2010, 212:485-499.
38. Bruijnzeel A.W., Ford J., Rogers J.A., Scheick S., Ji Y., Bishnoi M., Alexander J.C. Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. Pharmacol. Biochem. Behav. 2012, 101:62-68.
39. Bruijnzeel A.W., Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res. Brain Res. Rev. 2005, 49:505-528.
40. Bruijnzeel A.W., Prado M., Isaac S. Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. Biol. Psychiatry 2009, 66:110-117.
41. Bruijnzeel A.W., Zislis G., Wilson C., Gold M.S. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 2007, 32:955-963.
42. Buczek Y., Le A.D., Stewart J., Shaham Y. Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology 1999, 144:183-188.
43. Burkhoff A., Linemeyer D.L., Salon J.A. Distribution of a novel hypothalamic neuropeptide Y receptor gene and it's absence in rat. Brain Res. Mol. Brain Res. 1998, 53:311-316.
44. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R., Trendelenburg U. International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 1994, 46:121-136.
45. Caan B., Coates A., Schaefer C., Finkler L., Sternfeld B., Corbett K. Women gain weight 1 year after smoking cessation while dietary intake temporarily increases. J. Am. Diet. Assoc. 1996, 96:1150-1155.
46. Cahill, K., Stead, L.F., Lancaster, T., 2010. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev., Issue 12, Art. No.: CD006103, doi:10.1002/14651858.CD006103.pub4.
47. Cam G.R., Bassett J.R., Cairncross K.D. The action of nicotine on the pituitary-adrenal cortical axis. Arch. Int. Pharmacodyn. Ther. 1979, 237:49-66.
48. Carroll M.E. The role of food deprivation in the maintenance and reinstatement of cocaine-seeking behavior in rats. Drug Alcohol Depend. 1985, 16:95-109.
49. Castane A., Berrendero F., Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacol. Biochem. Behav. 2005, 81:381-386.
50. Cecchi M., Khoshbouei H., Javors M., Morilak D.A. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 2002, 112:13-21.
51. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., De Souza E.B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 1996, 17:166-172.
52. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. Suppl. 2003, 108(s417):38-50.
53. Charney D.S., Deutch A.Y., Krystal J.H., Southwick S.M., Davis M. Psychobiologic mechanisms of posttraumatic stress disorder. Arch. Gen. Psychiatry 1993, 50:295-305.
54. Charney D.S., Heninger G.R. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 1986, 43:1042-1054.
55. Charney D.S., Heninger G.R., Sternberg D.E., Redmond D.E., Leckman J.F., Maas J.W., Roth R.H. Presynaptic adrenergic receptor sensitivity in depression. The effect of long-term desipramine treatment. Arch. Gen. Psychiatry 1981, 38:1334-1340.
56. Charney D.S., Woods S.W., Krystal J.H., Nagy L.M., Heninger G.R. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr. Scand. 1992, 86:273-282.
57. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
58. Chen A.M., Perrin M.H., Digruccio M.R., Vaughan J.M., Brar B.K., Arias C.M., Lewis K.A., Rivier J.E., Sawchenko P.E., Vale W.W. A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2620-2625.
59. Chen H., Fu Y., Sharp B.M. Chronic nicotine self-administration augments hypothalamic-pituitary-adrenal responses to mild acute stress. Neuropsychopharmacology 2008, 33:721-730.
60. Chen H., Huang X., Guo X., Mailman R.B., Park Y., Kamel F., Umbach D.M., Xu Q., Hollenbeck A., Schatzkin A., Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010, 74:878-884.
61. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:8967-8971.
62. Cherek D.R. Effects of acute exposure to increased levels of background industrial noise on cigarette smoking behavior. Int. Arch. Occup. Environ. Health 1985, 56:23-30.
63. Cheskin L.J., Hess J.M., Henningfield J., Gorelick D.A. Calorie restriction increases cigarette use in adult smokers. Psychopharmacology 2005, 179:430-436.
64. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985, 15:1159-1181.
65. Cippitelli A., Damadzic R., Hansson A.C., Singley E., Sommer W.H., Eskay R., Thorsell A., Heilig M. Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Psychopharmacology 2010, 208:417-426.
66. Connolly G.N., Alpert H.R., Wayne G.F., Koh H. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997-2005. Tob. Control 2007, 16:e5.
67. Cook J., Jakupcak M., Rosenheck R., Fontana A., McFall M. Influence of PTSD symptom clusters on smoking status among help-seeking Iraq and Afghanistan veterans. Nicotine Tob. Res. 2009, 11:1189-1195.
68. Cook J.W., Spring B., McChargue D., Hedeker D. Hedonic capacity, cigarette craving, and diminished positive mood. Nicotine Tob. Res. 2004, 6:39-47.
69. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol. Biochem. Behav. 1989, 33:197-203.
70. Crooks P.A., Dwoskin L.P. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. 1997, 54:743-753.
71. Cryan J.F., Gasparini F., van Heeke G., Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov. Today 2003, 8:1025-1034.
72. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol. Psychiatry 2003, 54:49-58.
73. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
74. Cryan J.F., Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry 2004, 9:326-357.
75. Cryan J.F., Page M.E., Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur. J. Pharmacol. 2002, 436:197-205.
76. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 2005, 29:547-569.
77. Dahlström A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 1964, 232:1-55.
78. Damaj M.I., Carroll F.I., Eaton J.B., Navarro H.A., Blough B.E., Mirza S., Lukas R.J., Martin B.R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 2004, 66:675-682.
79. Damaj M.I., Kao W., Martin B.R. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J. Pharmacol. Exp. Ther. 2003, 307:526-534.
80. Dani J.A., Balfour D.J. Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci. 2011, 34:383-392.
81. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996, 16:905-908.
82. Date Y., Mondal M.S., Matsukura S., Ueta Y., Yamashita H., Kaiya H., Kangawa K., Nakazato M. Distribution of orexin/hypocretin in the rat median eminence and pituitary. Brain Res. Mol. Brain Res. 2000, 76:1-6.
83. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:748-753.
84. Davidson J. Seizures and bupropion: a review. J. Clin. Psychiatry 1989, 50:256-261.
85. Davis J.A., James J.R., Siegel S.J., Gould T.J. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J. Neurosci. 2005, 25:8708-8713.
86. Dayas C.V., Buller K.M., Crane J.W., Xu Y., Day T.A. Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur. J. Neurosci. 2001, 14:1143-1152.
87. De Biasi M., Dani J.A. Reward, addiction, withdrawal to nicotine. Annu. Rev. Neurosci. 2010, 34:105-130.
88. de Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 1998, 19:269-301.
89. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:322-327.
90. De Souza E.B., Insel T.R., Perrin M.H., Rivier J., Vale W.W., Kuhar M.J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J. Neurosci. 1985, 5:3189-3203.
91. De Wied D. Effects of peptide hormones on behavior. Frontiers in Neuroendocrinology 1969, Oxford University Press, London/New York, pp. 97-140.
92. De Wied D. Behavioral effects of neuropeptides related to ACTH, MSH, and betaLPH. Ann. N. Y. Acad. Sci. 1977, 297:263-274.
93. Delfs J.M., Zhu Y., Druhan J.P., Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000, 403:430-434.
94. Devoto P., Flore G., Pira L., Diana M., Gessa G.L. Co-release of noradrenaline and dopamine in the prefrontal cortex after acute morphine and during morphine withdrawal. Psychopharmacology 2002, 160:220-224.
95. Dierker L.C., Avenevoli S., Merikangas K.R., Flaherty B.P., Stolar M. Association between psychiatric disorders and the progression of tobacco use behaviors. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:1159-1167.
96. Dong J., Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 2001, 155:52-57.
97. Donny E.C., Caggiula A.R., Rose C., Jacobs K.S., Mielke M.M., Sved A.F. Differential effects of response-contingent and response-independent nicotine in rats. Eur. J. Pharmacol. 2000, 402:231-240.
98. Dube M.G., Kalra S.P., Kalra P.S. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res. 1999, 842:473-477.
99. Duman R.S., Nestler E.J. Signal transduction pathways for catecholamine receptors. Neuropsychopharmacology: The Fifth Generation of Progress 2002, Lippincott Williams & Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
100. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res. Brain Res. Rev. 1990, 15:71-100.
101. Eaves M., Thatcher-Britton K., Rivier J., Vale W., Koob G.F. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats. Peptides 1985, 6:923-926.
102. Eggermann E., Serafin M., Bayer L., Machard D., Saint-Mleux B., Jones B.E., Muhlethaler M. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001, 108:177-181.
103. Elias G.A., Gulick D., Wilkinson D.S., Gould T.J. Nicotine and extinction of fear conditioning. Neuroscience 2010, 165:1063-1073.
104. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998, 393:76-79.
105. Epstein D.H., Preston K.L., Stewart J., Shaham Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology 2006, 189:1-16.
106. Erb S., Hitchcott P.K., Rajabi H., Mueller D., Shaham Y., Stewart J. Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 2000, 23:138-150.
107. Farzin D., Mansouri N. Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol. 2006, 16:324-328.
108. Federal Trade Commission, 2000. Tar, Nicotine, and Carbon Monoxide of the Smoke of 1294 Varieties of Domestic Cigarettes For the Year 1998: A Federal Trade Commission Report to Congress.
109. Feldner M.T., Babson K.A., Zvolensky M.J. Smoking, traumatic event exposure, and post-traumatic stress: a critical review of the empirical literature. Clin. Psychol. Rev. 2007, 27:14-45.
110. Fenton H.M., Liebman J.M. Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. Pharmacol. Biochem. Behav. 1982, 17:1207-1212.
111. Fergusson D.M., Goodwin R.D., Horwood L.J. Major depression and cigarette smoking: results of a 21-year longitudinal study. Psychol. Med. 2003, 33:1357-1367.
112. Ferris R.M., Maxwell R.A., Cooper B.R., Soroko F.E. Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion. HCl - a new atypical antidepressant agent. Adv. Biochem. Psychopharmacol. 1982, 31:277-286.
113. Fidler J.A., West R. Self-perceived smoking motives and their correlates in a general population sample. Nicotine Tob. Res. 2009, 11:1182-1188.
114. File S.E., Kenny P.J., Ouagazzal A.M. Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav. Neurosci. 1998, 112:1423-1429.
115. Finkenauer R., Pomerleau C.S., Snedecor S.M., Pomerleau O.F. Race differences in factors relating to smoking initiation. Addict. Behav. 2009, 34:1056-1059.
116. Flory K., Hankin B.L., Kloos B., Cheely C., Turecki G. Alcohol and cigarette use and misuse among Hurricane Katrina survivors: psychosocial risk and protective factors. Subst. Use Misuse 2009, 44:1711-1724.
117. Forget B., Wertheim C., Mascia P., Pushparaj A., Goldberg S.R., Le F.B. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 2010, 35:1751-1760.
118. Fowler J.S., Logan J., Wang G.J., Volkow N.D. Monoamine oxidase and cigarette smoking. Neurotoxicology 2003, 24:75-82.
119. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Wolf A.P., Warner D., Cilento R., Zezulkova I. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J. Addict. Dis. 1998, 17:23-34.
120. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14065-14069.
121. Franklin J.C., Schiele B.C., Brozek J., Keys A. Observations on Human Behavior in Experimental Semistarvation and Rehabilitation 1948, pp. 28-45. 4th ed.
122. Frederick S.L., Reus V.I., Ginsberg D., Hall S.M., Munoz R.F., Ellman G. Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers. Biol. Psychiatry 1998, 43:525-530.
123. Freis E.D. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N. Engl. J. Med. 1954, 251:1006-1008.
124. Frenois F., Cador M., Caille S., Stinus L., Le M.C. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur. J. Neurosci. 2002, 16:1377-1389.
125. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288:88-92.
126. Fu Y., Matta S.G., Valentine J.D., Sharp B.M. Adrenocorticotropin response and nicotine-induced norepinephrine secretion in the rat paraventricular nucleus are mediated through brainstem receptors. Endocrinology 1997, 138:1935-1943.
127. Fuentealba J.A., Forray M.I., Gysling K. Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of the stria terminalis. J. Neurochem. 2000, 75:741-748.
128. George O., Ghozland S., Azar M.R., Cottone P., Zorrilla E.P., Parsons L.H., O'Dell L.E., Richardson H.N., Koob G.F. CRF CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17198-17203.
129. Gilbert D.G., Meliska C.J., Williams C.L., Jensen R.A. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology 1992, 106:275-281.
130. Gilpin N.W., Misra K., Koob G.F. Neuropeptide Y in the central nucleus of the amygdala suppresses dependence-induced increases in alcohol drinking. Pharmacol. Biochem. Behav. 2008, 90:475-480.
131. Gilpin N.W., Stewart R.B., Murphy J.M., Li T.K., Badia-Elder N.E. Neuropeptide Y reduces oral ethanol intake in alcohol-preferring (P) rats following a period of imposed ethanol abstinence. Alcohol Clin. Exp. Res. 2003, 27:787-794.
132. Glassman A.H., Helzer J.E., Covey L.S., Cottler L.B., Stetner F., Tipp J.E., Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990, 264:1546-1549.
133. Goeders N.E. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 2002, 27:13-33.
134. Gold M.S., Pottash A.C., Sweeney D.R., Extein I., Annitto W.J. Opiate detoxification with lofexidine. Drug Alcohol Depend. 1981, 8:307-315.
135. Gold M.S., Redmond D.E., Kleber H.D. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978, 2:599-602.
136. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
137. Gonzalez-Maeso J., Rodriguez-Puertas R., Meana J.J., Garcia-Sevilla J.A., Guimon J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol. Psychiatry 2002, 7:755-767.
138. Goodman E., Capitman J. Depressive symptoms and cigarette smoking among teens. Pediatrics 2000, 106:748-755.
139. Goodwin F.K., Bunney W.E. Depressions following reserpine: a reevaluation. Semin. Psychiatry 1971, 3:435-448.
140. Gould T.J. Nicotine and hippocampus-dependent learning: implications for addiction. Mol. Neurobiol. 2006, 34:93-107.
141. Gould T.J., Higgins J.S. Nicotine enhances contextual fear conditioning in C57BL/6J mice at 1 and 7 days post-training. Neurobiol. Learn. Mem. 2003, 80:147-157.
142. Gould T.J., Wehner J.M. Nicotine enhancement of contextual fear conditioning. Behav. Brain Res. 1999, 102:31-39.
143. Gourlay, S.G., Stead, L.F., Benowitz, N.L., 2004. Clonidine for smoking cessation. Cochrane Database Syst. Rev., Issue 3, Art. No.: CD000058.
144. Gregor P., Feng Y., DeCarr L.B., Cornfield L.J., McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 1996, 271:27776-27781.
145. Grimm J.W., Hope B.T., Wise R.A., Shaham Y. Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 2001, 412:141-142.
146. Hall S.M., Reus V.I., Munoz R.F., Sees K.L., Humfleet G., Hartz D.T., Frederick S., Triffleman E. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 1998, 55:683-690.
147. Hauptmann N., Shih J.C. 2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci. 2001, 68:1231-1241.
148. Heilig M., Wahlestedt C., Ekman R., Widerlov E. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur. J. Pharmacol. 1988, 147:465-467.
149. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjogren M., Asberg M., Ekman R., Wahlestedt C., Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 2004, 38:113-121.
150. Helton D.R., Modlin D.L., Tizzano J.P., Rasmussen K. Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology 1993, 113:205-210.
151. Herraiz T., Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 2005, 326:378-386.
152. Heyser C.J., Moc K., Koob G.F. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003, 28:1463-1471.
153. Heyser C.J., Schulteis G., Koob G.F. Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol Clin. Exp. Res. 1997, 21:784-791.
154. Hieble J.P., Bylund D.B., Clarke D.E., Eikenburg D.C., Langer S.Z., Lefkowitz R.J., Minneman K.P., Ruffolo R.R. International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol. Rev. 1995, 47:267-270.
155. Holahan M.R., Kalin N.H., Kelley A.E. Microinfusion of corticotropin-releasing factor into the nucleus accumbens shell results in increased behavioral arousal and oral motor activity. Psychopharmacology 1997, 130:189-196.
156. Hollander J.A., Lu Q., Cameron M.D., Kamenecka T.M., Kenny P.J. Insular hypocretin transmission regulates nicotine reward. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19480-19485.
157. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 2003 Nov., 24:580-588.
158. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Arch. Gen. Psychiatry 1991, 48:52-59.
159. Hughes J.R., Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 1986, 43:289-294.
160. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 1986, 143:993-997.
161. Hughes J.R., Keely J., Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004, 99:29-38.
162. Hughes, J.R., Stead, L.F., Lancaster, T., 2007. Antidepressants for smoking cessation. Cochrane Database Syst. Rev., Issue 1, Art. No.: CD000031, doi:10.1002/14651858.CD000031.pub3.
163. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., Khayrallah M.A., Schroeder D.R., Glover P.N., Sullivan C.R., Croghan I.T., Sullivan P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997, 337:1195-1202.
164. Husum H., Mikkelsen J.D., Hogg S., Mathe A.A., Mork A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000, 39:1463-1473.
165. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994, 9(Suppl. 1):19-26.
166. Ikard F.F., Green D.E., Horn D. A Scale to Differentiate between Types of Smoking as Related to the Management of Affect 1969, pp. 649-659. 4th ed.
167. Irvine E.E., Cheeta S., File S.E. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav. Pharmacol. 1999, 10:691-697.
168. Irvine E.E., Cheeta S., File S.E. Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol. Biochem. Behav. 2001, 68:319-325.
169. Ishida H., Shirayama Y., Iwata M., Katayama S., Yamamoto A., Kawahara R., Nakagome K. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007, 17:271-280.
170. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res. 1999, 850:189-196.
171. Jain M.R., Horvath T.L., Kalra P.S., Kalra S.P. Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regul. Pept. 2000, 87:19-24.
172. Jarvis M.J. Why people smoke. BMJ 2004, 328:277-279.
173. Jaszberenyi M., Bujdoso E., Pataki I., Telegdy G. Effects of orexins on the hypothalamic-pituitary-adrenal system. J. Neuroendocrinol. 2000, 12:1174-1178.
174. Johnson J.G., Cohen P., Pine D.S., Klein D.F., Kasen S., Brook J.S. Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA 2000, 284:2348-2351.
175. Johnson P.M., Hollander J.A., Kenny P.J. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol. Biochem. Behav. 2008, 90:409-415.
176. Johnston J.A., Lineberry C.G., Ascher J.A., Davidson J., Khayrallah M.A., Feighner J.P., Stark P. A 102-center prospective study of seizure in association with bupropion. J. Clin. Psychiatry 1991, 52:450-456.
177. Johren O., Neidert S.J., Kummer M., Dendorfer A., Dominiak P. Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 2001, 142:3324-3331.
178. Jonkman S., Henry B., Semenova S., Markou A. Mild anxiogenic effects of nicotine withdrawal in mice. Eur. J. Pharmacol. 2005, 516:40-45.
179. Jonkman S., Risbrough V.B., Geyer M.A., Markou A. Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology 2008, 33:2131-2138.
180. Jorenby D.E., Hatsukami D.K., Smith S.S., Fiore M.C., Allen S., Jensen J., Baker T.B. Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology 1996, 128:130-138.
181. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999, 340:685-691.
182. Joseph S., Yule W., Williams R., Hodgkinson P. Increased substance use in survivors of the Herald of Free Enterprise disaster. Br. J. Med. Psychol. 1993, 66(Pt 2):185-191.
183. Kalra S.P., Kalra P.S. NPY: A novel on/off switch for control of appetite and reproduction. Neuropeptide Y and Related Peptides 2004, 221-249. Springer, Berlin. M.C. Michel (Ed.).
184. Kane J.K., Parker S.L., Li M.D. Hypothalamic orexin-A binding sites are downregulated by chronic nicotine treatment in the rat. Neurosci. Lett. 2001, 298:1-4.
185. Kane J.K., Parker S.L., Matta S.G., Fu Y., Sharp B.M., Li M.D. Nicotine up-regulates expression of orexin and its receptors in rat brain. Endocrinology 2000, 141:3623-3629.
186. Karteris E., Machado R.J., Chen J., Zervou S., Hillhouse E.W., Randeva H.S. Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E1089-E1100.
187. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 2002, 26:259-283.
188. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 1997, 74:299-316.
189. Khoshbouei H., Cecchi M., Dove S., Javors M., Morilak D.A. Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol. Biochem. Behav. 2002, 71:407-417.
190. Kinnunen T., Doherty K., Militello F.S., Garvey A.J. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J. Consult. Clin. Psychol. 1996, 64:791-798.
191. Kirschbaum C., Wust S., Strasburger C.J. 'Normal' cigarette smoking increases free cortisol in habitual smokers. Life Sci. 1992, 50:435-442.
192. Koenen K.C., Hitsman B., Lyons M.J., Niaura R., McCaffery J., Goldberg J., Eisen S.A., True W., Tsuang M. A twin registry study of the relationship between posttraumatic stress disorder and nicotine dependence in men. Arch. Gen. Psychiatry 2005, 62:1258-1265.
193. Koob G.F. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996, 16:893-896.
194. Koob G.F. Stress, corticotropin-releasing factor, and drug addiction. Ann. N. Y. Acad. Sci. 1999, 897:27-45.
195. Koob G.F. A role for brain stress systems in addiction. Neuron 2008, 59:11-34.
196. Koob G.F., Ahmed S.H., Boutrel B., Chen S.A., Kenny P.J., Markou A., O'Dell L.E., Parsons L.H., Sanna P.P. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci. Biobehav. Rev. 2004, 27:739-749.
197. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 1999, 848:141-152.
198. Kostich W.A., Chen A., Sperle K., Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol. Endocrinol. 1998, 12:1077-1085.
199. Kuru M., Ueta Y., Serino R., Nakazato M., Yamamoto Y., Shibuya I., Yamashita H. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 2000, 11:1977-1980.
200. Lader D. Smoking-Related Behaviour and Attitudes, 2007 2007, Office of National Statistics, London.
201. Lambe E.K., Liu R.J., Aghajanian G.K. Schizophrenia, hypocretin (orexin), and the thalamocortical activating system. Schizophr. Bull. 2007, 33:1284-1290.
202. Lang W.J., Latiff A.A., Mcqueen A., Singer G. Self administration of nicotine with and without a food delivery schedule. Pharmacol. Biochem. Behav. 1977, 7:65-70.
203. Langer S.Z. Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 1980, 32:337-362.
204. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. JAMA 2000, 284:2606-2610.
205. Lawrence D., Mitrou F., Zubrick S.R. Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009, 9:285.
206. Leao R.M., Cruz F.C., Planeta C.S. Exposure to acute restraint stress reinstates nicotine-induced place preference in rats. Behav. Pharmacol. 2009, 20:109-113.
207. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
208. LeSage M.G., Perry J.L., Kotz C.M., Shelley D., Corrigall W.A. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology 2010, 209:203-212.
209. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7570-7575.
210. Liebman J.M., Hall N., Prowse J. Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. Pharmacol. Biochem. Behav. 1982, 16:785-790.
211. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
212. Lin Y., de Vaca S.C., Carr K.D., Stone E.A. Role of alpha(1)-adrenoceptors of the locus coeruleus in self-stimulation of the medial forebrain bundle. Neuropsychopharmacology 2007, 32:835-841.
213. Lingjaerde O. Tetrabenazine (nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine. Acta Psychiatr. Scand. 1963, 39(Suppl. 170):1-109.
214. Lopez M., Senaris R., Gallego R., Garcia-Caballero T., Lago F., Seoane L., Casanueva F., Dieguez C. Orexin receptors are expressed in the adrenal medulla of the rat. Endocrinology 1999, 140:5991-5994.
215. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:836-840.
216. Lundberg J.M., Terenius L., Hokfelt T., Goldstein M. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci. Lett. 1983, 42:167-172.
217. Lutfy K., Brown M.C., Nerio N., Aimiuwu O., Tran B., Anghel A., Friedman T.C. Repeated stress alters the ability of nicotine to activate the hypothalamic-pituitary-adrenal axis. J. Neurochem. 2006, 99:1321-1327.
218. Maldonado R., Berrendero F. Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Curr. Drug Targets 2010, 11:440-449.
219. Maley B.E., Seybold V.S. Distribution of [3H]quinuclidinyl benzilate, [3H]nicotine, and [125I]alpha-bungarotoxin binding sites in the nucleus tractus solitarii of the cat. J. Comp. Neurol. 1993, 327:194-204.
220. Malin D.H., Lake J.R., Newlin-Maultsby P., Roberts L.K., Lanier J.G., Carter V.A., Cunningham J.S., Wilson O.B. Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 1992, 43:779-784.
221. Mantsch J.R., Katz E.S. Elevation of glucocorticoids is necessary but not sufficient for the escalation of cocaine self-administration by chronic electric footshock stress in rats. Neuropsychopharmacology 2007, 32:367-376.
222. Marcinkiewcz C.A., Prado M.M., Isaac S.K., Marshall A., Rylkova D., Bruijnzeel A.W. Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 2009, 34:1743-1752.
223. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., Elmquist J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001, 435:6-25.
224. Markou A. Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression?. Biol. Psychiatry 2007, 61:17-22.
225. Massachusetts Department of Public Health, 2010. Change in nicotine yields 1998-2004.
226. Mathew R.J., Weinman M.L., Mirabi M. Physical symptoms of depression. Br. J. Psychiatry 1981, 139:293-296.
227. Matta S.G., Beyer H.S., McAllen K.M., Sharp B.M. Nicotine elevates rat plasma ACTH by a central mechanism. J. Pharmacol. Exp. Ther. 1987, 243:217-226.
228. Matta S.G., Foster C.A., Sharp B.M. Nicotine stimulates the expression of cFos protein in the parvocellular paraventricular nucleus and brainstem catecholaminergic regions. Endocrinology 1993, 132:2149-2156.
229. Matta S.G., Foster C.A., Sharp B.M. Selective administration of nicotine into catecholaminergic regions of rat brainstem stimulates adrenocorticotropin secretion. Endocrinology 1993, 133:2935-2942.
230. Matta S.G., Fu Y., Valentine J.D., Sharp B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998, 23:103-113.
231. Matta S.G., Singh J., Sharp B.M. Catecholamines mediate nicotine-induced adrenocorticotropin secretion via alpha-adrenergic receptors. Endocrinology 1990, 127:1646-1655.
232. McEwen A., West R., McRobbie H. Motives for smoking and their correlates in clients attending stop smoking treatment services. Nicotine Tob. Res. 2008, 10:843-850.
233. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000, 886:172-189.
234. Mendelson J.H., Goletiani N., Sholar M.B., Siegel A.J., Mello N.K. Effects of smoking successive low- and high-nicotine cigarettes on hypothalamic-pituitary-adrenal axis hormones and mood in men. Neuropsychopharmacology 2008, 33:749-760.
235. Mendelson J.H., Sholar M.B., Goletiani N., Siegel A.J., Mello N.K. Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005, 30:1751-1763.
236. Merlo Pich E., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 1995, 15:5439-5447.
237. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50:143-150.
238. Moffett M.C., Goeders N.E. CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology 2007, 190:171-180.
239. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA 2004, 291:1238-1245.
240. Moore R.Y., Card J.P. Noradrenaline-containing neuron systems. Handbook of Chemical Neuroanatomy 1984, 123-156. Elsevier, Amsterdam. A. Bjorklund, T. Hokfelt (Eds.).
241. Moore T.J., Furberg C.D. Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ 2009, 339:b4964.
242. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?. Neurology 1995, 45:1041-1051.
243. Morgan J.I., Curran T. Immediate-early genes: ten years on. Trends Neurosci. 1995, 18:66-67.
244. Morilak D.A., Barrera G., Echevarria D.J., Garcia A.S., Hernandez A., Ma S., Petre C.O. Role of brain norepinephrine in the behavioral response to stress. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:1214-1224.
245. Mullins D., Kirby D., Hwa J., Guzzi M., Rivier J., Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 2001, 60:534-540.
246. Muzzin P., Revelli J.P., Kuhne F., Gocayne J.D., McCombie W.R., Venter J.C., Giacobino J.P., Fraser C.M. An adipose tissue-specific beta-adrenergic receptor, molecular cloning and down-regulation in obesity. J. Biol. Chem. 1991, 266:24053-24058.
247. Myers W.D., Ng K.T., Singer G. Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. Pharmacol. Biochem. Behav. 1982, 17:807-811.
248. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999, 827:243-260.
249. Nandi A., Galea S., Ahern J., Vlahov D. Probable cigarette dependence, PTSD, and depression after an urban disaster: results from a population survey of New York city residents 4 months after September 11, 2001. Psychiatry 2005, 68:299-310.
250. Nelson J.C. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol. Psychiatry 1999, 46:1301-1308.
251. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
252. Niaura R., Britt D.M., Shadel W.G., Goldstein M., Abrams D., Brown R. Symptoms of depression and survival experience among three samples of smokers trying to quit. Psychol. Addict. Behav. 2001, 15:13-17.
253. Nichter M., Nichter M., Vuckovic N., Quintero G., Ritenbaugh C. Smoking experimentation and initiation among adolescent girls: qualitative and quantitative findings. Tob. Control 1997, 6:285-295.
254. Nijsen M.J., Croiset G., Diamant M., de W.D., Wiegant V.M. CRH signalling in the bed nucleus of the stria terminalis is involved in stress-induced cardiac vagal activation in conscious rats. Neuropsychopharmacology 2001, 24:1-10.
255. O'Connor E.C., Parker D., Rollema H., Mead A.N. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 2010, 208:365-376.
256. O'Dell L.E., Koob G.F. 'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. Pharmacol. Biochem. Behav. 2007, 86:346-353.
257. Olive M.F., Koenig H.N., Nannini M.A., Hodge C.W. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol. Biochem. Behav. 2002, 72:213-220.
258. Ouagazzal A.M., Kenny P.J., File S.E. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 1999, 144:54-60.
259. Pacak K., Palkovits M., Kopin I.J., Goldstein D.S. Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. Front. Neuroendocrinol. 1995, 16:89-150.
260. Panagis G., Hildebrand B.E., Svensson T.H., Nomikos G.G. Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 2000, 35:15-25.
261. Parrott A.C. Individual differences in stress and arousal during cigarette smoking. Psychopharmacology 1994, 115:389-396.
262. Parrott A.C. Stress modulation over the day in cigarette smokers. Addiction 1995, 90:233-244.
263. Parrott A.C. Does cigarette smoking cause stress?. Am. Psychol. 1999, 54:817-820.
264. Parslow R.A., Jorm A.F. Tobacco use after experiencing a major natural disaster: analysis of a longitudinal study of 2063 young adults. Addiction 2006, 101:1044-1050.
265. Pasumarthi R.K., Reznikov L.R., Fadel J. Activation of orexin neurons by acute nicotine. Eur. J. Pharmacol. 2006, 535:172-176.
266. Paterson N.E., Froestl W., Markou A. Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 2005, 30:119-128.
267. Patton G.C., Carlin J.B., Coffey C., Wolfe R., Hibbert M., Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am. J. Public Health 1998, 88:1518-1522.
268. Pauly J.R., Collins A.C. An autoradiographic analysis of alterations in nicotinic cholinergic receptors following 1 week of corticosterone supplementation. Neuroendocrinology 1993, 57:262-271.
269. Pauly J.R., Grun E.U., Collins A.C. Chronic corticosterone administration modulates nicotine sensitivity and brain nicotinic receptor binding in C3H mice. Psychopharmacology 1990, 101:310-316.
270. Pauly J.R., Grun E.U., Collins A.C. Tolerance to nicotine following chronic treatment by injections: a potential role for corticosterone. Psychopharmacology 1992, 108:33-39.
271. Pauly J.R., Marks M.J., Gross S.D., Collins A.C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J. Pharmacol. Exp. Ther. 1991, 258:1127-1136.
272. Pauly J.R., Marks M.J., Robinson S.F., van de Kamp J.L., Collins A.C. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J. Pharmacol. Exp. Ther. 1996, 278:361-369.
273. Pauly J.R., Ullman E.A., Collins A.C. Adrenocortical hormone regulation of nicotine sensitivity in mice. Physiol. Behav. 1988, 44:109-116.
274. Perkins K.A., Grobe J.E. Increased desire to smoke during acute stress. Br. J. Addict. 1992, 87:1037-1040.
275. Perrin M.H., Donaldson C.J., Chen R., Lewis K.A., Vale W.W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993, 133:3058-3061.
276. Piazza P.V., Le Moal M.L. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu. Rev. Pharmacol. Toxicol. 1996, 36:359-378.
277. Piazza P.V., Maccari S., Deminiere J.M., Le M.M., Mormede P., Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2088-2092.
278. Piazza P.V., Marinelli M., Jodogne C., Deroche V., Rouge-Pont F., Maccari S., Le M.M., Simon H. Inhibition of corticosterone synthesis by Metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration. Brain Res. 1994, 658:259-264.
279. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106.
280. Piper M.E., Smith S.S., Schlam T.R., Fleming M.F., Bittrich A.A., Brown J.L., Leitzke C.J., Zehner M.E., Fiore M.C., Baker T.B. Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J. Consult. Clin. Psychol. 2010, 78:13-23.
281. Pisarchik A., Slominski A.T. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 2001, 15:2754-2756.
282. Plaza-Zabala A., Flores A., Maldonado R., Berrendero F. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biol. Psychiatry 2012, 71:214-223.
283. Plaza-Zabala A., Martin-Garcia E., de L.L., Maldonado R., Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J. Neurosci. 2010, 30:2300-2310.
284. Porsolt R.D., Le P.M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
285. Prinstein M.J., La Greca A.M. Childhood depressive symptoms and adolescent cigarette use: a six-year longitudinal study controlling for peer relations correlates. Health Psychol. 2009, 28:283-291.
286. Prochazka A.V., Petty T.L., Nett L., Silvers G.W., Sachs D.P., Rennard S.I., Daughton D.M., Grimm R.H., Heim C. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch. Intern. Med. 1992, 152:2065-2069.
287. Prochazka A.V., Weaver M.J., Keller R.T., Fryer G.E., Licari P.A., Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 1998, 158:2035-2039.
288. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 1993, 605:25-32.
289. Reader S.C., Alaghband-Zadeh J., Daly J.R., Robertson W.R. Negative rate-sensitive feedback effects on adrenocorticotrophin secretion by cortisol in normal subjects. J. Endocrinol. 1982, 92:443-448.
290. Redrobe J.P., Carvajal C., Kask A., Dumont Y., Quirion R. Neuropeptide Y and its receptor subtypes in the central nervous system: emphasis on their role in animal models of psychiatric disorders. Neuropeptide Y and Related Peptides 2004, 101-136. Springer, Berlin. M.C. Michel (Ed.).
291. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
292. Reijneveld S.A., Crone M.R., Verhulst F.C., Verloove-Vanhorick S.P. The effect of a severe disaster on the mental health of adolescents: a controlled study. Lancet 2003, 362:691-696.
293. Rezvani A.H., Levin E.D. Cognitive effects of nicotine. Biol. Psychiatry 2001, 49:258-267.
294. Richter R.M., Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 1999, 32:254-261.
295. Robinson S.F., Grun E.U., Pauly J.R., Collins A.C. Changes in sensitivity to nicotine and brain nicotinic receptors following chronic nicotine and corticosterone treatments in mice. Pharmacol. Biochem. Behav. 1996, 54:587-593.
296. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
297. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol. Sci. 2007, 28:316-325.
298. Rose J.E., Ananda S., Jarvik M.E. Cigarette smoking during anxiety-provoking and monotonous tasks. Addict. Behav. 1983, 8:353-359.
299. Ruffolo R.R., Hieble J.P. Alpha-adrenoceptors. Pharmacol. Ther. 1994, 61:1-64.
300. Russell S.H., Small C.J., Dakin C.L., Abbott C.R., Morgan D.G., Ghatei M.A., Bloom S.R. The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. J. Neuroendocrinol. 2001, 13:561-566.
301. Rygula R., Abumaria N., Flugge G., Fuchs E., Ruther E., Havemann-Reinecke U. Anhedonia and motivational deficits in rats: impact of chronic social stress. Behav. Brain Res. 2005, 162:127-134.
302. Rylkova D., Boissoneault J., Isaac S., Prado M., Shah H.P., Bruijnzeel A.W. Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides 2008, 42:215-227.
303. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
304. Sallee F.R., Sethuraman G., Sine L., Liu H. Yohimbine challenge in children with anxiety disorders. Am. J. Psychiatry 2000, 157:1236-1242.
305. Samson W.K., Bagley S.L., Ferguson A.V., White M.M. Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R382-R387.
306. Sapolsky R.M. Do glucocorticoid concentrations rise with age in the rat?. Neurobiol. Aging 1992, 13:171-174.
307. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
308. Schweimer J., Fendt M., Schnitzler H.U. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats. Eur. J. Pharmacol. 2005, 507:117-124.
309. Semenova S., Markou A. The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur. Neuropsychopharmacol. 2010, 20:731-746.
310. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
311. Shalev U., Highfield D., Yap J., Shaham Y. Stress and relapse to drug seeking in rats: studies on the generality of the effect. Psychopharmacology 2000, 150:337-346.
312. Shalev U., Marinelli M., Baumann M.H., Piazza P.V., Shaham Y. The role of corticosterone in food deprivation-induced reinstatement of cocaine seeking in the rat. Psychopharmacology 2003, 168:170-176.
313. Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A., Gnys M., Evoniuk G., DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 2000, 148:33-40.
314. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22:197-217.
315. Shine J., Potter E.K., Biden T., Selbie L.A., Herzog H. Neuropeptide Y and regulation of the cardiovascular system. J. Hypertens. Suppl. 1994, 12:S41-S45.
316. Shoaib M., Shippenberg T.S. Adrenalectomy attenuates nicotine-induced dopamine release and locomotor activity in rats. Psychopharmacology 1996, 128:343-350.
317. Sinclair J.D., Senter R.J. Development of an alcohol-deprivation effect in rats. Q. J. Stud. Alcohol 1968, 29:863-867.
318. Singer G., Simpson F., Lang W.J. Schedule induced self injections of nicotine with recovered body weight. Pharmacol. Biochem. Behav. 1978, 9:387-389.
319. Singewald N., Salchner P., Sharp T. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry 2003, 53:275-283.
320. Singh S., Loke Y.K., Spangler J.G., Furberg C.D. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
321. Small E., Shah H.P., Davenport J.J., Geier J.E., Yavarovich K.R., Yamada H., Sabarinath S.N., Derendorf H., Pauly J.R., Gold M.S., Bruijnzeel A.W. Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology 2010, 208:143-158.
322. Smith B.R., Amit Z., Splawinsky J. Conditioned place preference induced by intraventricular infusions of acetaldehyde. Alcohol 1984, 1:193-195.
323. Song C., Earley B., Leonard B.E. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav. Immun. 1996, 10:1-16.
324. Sonntag H., Wittchen H.U., Hofler M., Kessler R.C., Stein M.B. Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults?. Eur. Psychiatry 2000, 15:67-74.
325. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 2004, 77:723-729.
326. Southwick S.M., Krystal J.H., Bremner J.D., Morgan C.A., Nicolaou A.L., Nagy L.M., Johnson D.R., Heninger G.R., Charney D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 1997, 54:749-758.
327. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., Heninger G.R., Charney D.S. Abnormal noradrenergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 1993, 50:266-274.
328. Spyraki C., Fibiger H.C. Functional evidence for subsensitivity of noradrenergic alpha 2 receptors after chronic desipramine treatment. Life Sci. 1980, 27:1863-1867.
329. Stahl S.M., Entsuah R., Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry 2002, 52:1166-1174.
330. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry 1999, 46:1480-1508.
331. Steptoe A., Ussher M. Smoking, cortisol and nicotine. Int. J. Psychophysiol. 2006, 59:228-235.
332. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 2000, 387:R9-R10.
333. Stolerman I.P., Fink R., Jarvik M.E. Acute and chronic tolerance to nicotine measured by activity in rats. Psychopharmacologia 1973, 30:329-342.
334. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology 1995, 117:2-10.
335. Sutton R.E., Koob G.F., Le Moal M., Rivier J., Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982, 297:331-333.
336. Swan G.E., Ward M.M., Carmelli D., Jack L.M. Differential rates of relapse in subgroups of male and female smokers. J. Clin. Epidemiol. 1993, 46:1041-1053.
337. Swanson C.J., Perry K.W., Schoepp D.D. The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. J. Neurochem. 2004, 88:194-202.
338. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
339. Talhout R., Opperhuizen A., van Amsterdam J.G. Role of acetaldehyde in tobacco smoke addiction. Eur. Neuropsychopharmacol. 2007, 17:627-636.
340. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
341. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
342. Thiele T.E., Heilig M. Behavioral effects of neuropeptide Y. Neuropeptide Y and Related Peptides 2004, 251-282. Springer, Berlin. M.C. Michel (Ed.).
343. Thiele T.E., Marsh D.J., Ste M.L., Bernstein I.L., Palmiter R.D. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998, 396:366-369.
344. Thorsell A., Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 2002, 36:182-193.
345. Thorsell A., Repunte-Canonigo V., O'Dell L.E., Chen S.A., King A.R., Lekic D., Koob G.F., Sanna P.P. Viral vector-induced amygdala NPY overexpression reverses increased alcohol intake caused by repeated deprivations in Wistar rats. Brain 2007, 130:1330-1337.
346. Thorsell A., Slawecki C.J., Ehlers C.L. Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with chronic ethanol exposure. Behav. Brain Res. 2005, 161:133-140.
347. Totsuka Y., Ushiyama H., Ishihara J., Sinha R., Goto S., Sugimura T., Wakabayashi K. Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Cancer Lett. 1999, 143:139-143.
348. Tsujino N., Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol. Rev. 2009, 61:162-176.
349. Ussher M., West R., Evans P., Steptoe A., McEwen A., Clow A., Hucklebridge F. Reduction in cortisol after smoking cessation among users of nicotine patches. Psychosom. Med. 2006, 68:299-306.
350. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
351. Van der Velden P.G., Grievink L., Olff M., Gersons B.P., Kleber R.J. Smoking as a risk factor for mental health disturbances after a disaster: a prospective comparative study. J. Clin. Psychiatry 2007, 68:87-92.
352. Van der Velden P.G., Kleber R.J., Koenen K.C. Smoking predicts posttraumatic stress symptoms among rescue workers: a prospective study of ambulance personnel involved in the Enschede Fireworks Disaster. Drug Alcohol Depend. 2008, 94:267-271.
353. Vlahov D., Galea S., Ahern J., Resnick H., Boscarino J.A., Gold J., Bucuvalas M., Kilpatrick D. Consumption of cigarettes, alcohol, and marijuana among New York City residents six months after the September 11 terrorist attacks. Am. J. Drug Alcohol Abuse 2004, 30:385-407.
354. Vlahov D., Galea S., Ahern J., Resnick H., Kilpatrick D. Sustained increased consumption of cigarettes, alcohol, and marijuana among Manhattan residents after September 11, 2001. Am. J. Public Health 2004, 94:253-254.
355. Wagena E.J., Knipschild P., Zeegers M.P. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005, 100:317-326.
356. Wahlestedt C., Blendy J.A., Kellar K.J., Heilig M., Widerlov E., Ekman R. Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res. 1990, 507:65-68.
357. Walter A., Mai J.K., Jimenez-Hartel W. Mapping of neuropeptide Y-like immunoreactivity in the human forebrain. Brain Res. Bull. 1990, 24:297-311.
358. Watanabe T., Nakagawa T., Yamamoto R., Maeda A., Minami M., Satoh M. Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology 2003, 170:80-88.
359. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. 2000, 292:1053-1064.
360. Weiner E.D., Mallat A.M., Papolos D.F., Lachman H.M. Acute lithium treatment enhances neuropeptide Y gene expression in rat hippocampus. Brain Res. Mol. Brain Res. 1992, 12:209-214.
361. Weiss J.M., Goodman P.A., Losito B.G., Corrigan S., Charry J.M., Bailey W.H. Behavioral Depression Produced by an Uncontrollable Stressor: Relationship to Norepinephrine, Dopamine, and Serotonin Levels in Various Regions of Rat Brain 1981, pp. 167-205. 3rd ed.
362. Weiss J.W., Palmer P.H., Chou C.P., Mouttapa M., Johnson C.A. Association between psychological factors and adolescent smoking in seven cities in China. Int. J. Behav. Med. 2008, 15:149-156.
363. Wesnes K., Warburton D.M. Smoking, nicotine and human performance. Pharmacol. Ther. 1983, 21:189-208.
364. Widdowson P.S., Ordway G.A., Halaris A.E. Reduced neuropeptide Y concentrations in suicide brain. J. Neurochem. 1992, 59:73-80.
365. Widerlov E., Lindstrom L.H., Wahlestedt C., Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J. Psychiatr. Res. 1988, 22:69-79.
366. Wilkins J.N., Carlson H.E., Van Vunakis H., Hill M.A., Gritz E., Jarvik M.E. Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology 1982, 78:305-308.
367. Wills T.A., Sandy J.M., Yaeger A.M. Stress and smoking in adolescence: a test of directional hypotheses. Health Psychol. 2002, 21:122-130.
368. Winternitz W.W., Quillen D. Acute hormonal response to cigarette smoking. J. Clin. Pharmacol. 1977, 17:389-397.
369. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 1996, 6:243-251.
370. Woldbye D.P., Klemp K., Madsen T.M. Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors. J. Pharmacol. Exp. Ther. 1998, 284:633-636.
371. Woldbye D.P., Ulrichsen J., Haugbol S., Bolwig T.G. Ethanol withdrawal in rats is attenuated by intracerebroventricular administration of neuropeptide Y. Alcohol Alcohol. 2002, 37:318-321.
372. World Health Organization, 2009. WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments.
373. World Health Organization, 2011. Systematic review of the link between tobacco and poverty.
374. Wu L.T., Anthony J.C. Tobacco smoking and depressed mood in late childhood and early adolescence. Am. J. Public Health 1999, 89:1837-1840.
375. Yamada H., Bruijnzeel A.W. Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 2011, 60:303-311.
376. Yamanaka A., Sakurai T., Katsumoto T., Yanagisawa M., Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res. 1999, 849:248-252.
377. Yannielli P.C., Harrington M.E. Neuropeptide Y in the mammalian circadian system: effects on light-induced circadian responses. Peptides 2001, 22:547-556.
378. Yates S.L., Bencherif M., Fluhler E.N., Lippiello P.M. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem. Pharmacol. 1995, 50:2001-2008.
379. Zaniewska M., McCreary A.C., Wydra K., Filip M. Effects of serotonin (5-HT)(2) receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology 2010, 58:1140-1146.
380. Zarcone V. Narcolepsy. N. Engl. J. Med. 1973, 288:1156-1166.
381. Zhdanova I.V., Piotrovskaya V.R. Melatonin treatment attenuates symptoms of acute nicotine withdrawal in humans. Pharmacol. Biochem. Behav. 2000, 67:131-135.
382. Zislis G., Desai T.V., Prado M., Shah H.P., Bruijnzeel A.W. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007, 58:958-966.
383. Zmijewski M.A., Slominski A.T. Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim. Pol. 2010, 57:1-13.
384. Zoli M., Lena C., Picciotto M.R., Changeux J.P. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J. Neurosci. 1998, 18:4461-4472.
385. Zvolensky M.J., Gibson L.E., Vujanovic A.A., Gregor K., Bernstein A., Kahler C., Legues C.W., Brown R.A., Feldner M.T. Impact of posttraumatic stress disorder on early smoking lapse and relapse during a self-guided quit attempt among community-recruited daily smokers. Nicotine Tob. Res. 2008, 10:1415-1427.
386. Zvolensky M.J., Stewart S.H., Vujanovic A.A., Gavric D., Steeves D. Anxiety sensitivity and anxiety and depressive symptoms in the prediction of early smoking lapse and relapse during smoking cessation treatment. Nicotine Tob. Res. 2009, 11:323-331.